News

PS-Fertility, maker of a male fertility test, to establish HQ outside Charlottesville

Life sciences startup PS-Fertility Inc. will invest $1.4 million to build out a headquarters and laboratory in Albemarle County, the office of Virginia Gov. Glenn Youngkin announced Wednesday.

PS-Fertility is aiming to commercialize a male fertility diagnostic that was originally developed at the University of Virginia. The company will lease 4,000 square feet at 3030 Vision Lane, just south of Charlottesville’s city limits, for its headquarters and lab as well as a test kit assembly operation, according to the announcement. PS-Fertility said it plans to create 31 new jobs with the project.

The company’s diagnostic tests for the presence of a biomarker on sperm cells necessary for fertilization, which can offer information on male fertility. PS-Fertility plans to use an at-home collection model, where samples are mailed to the new lab from across the country.

CEO Kevin Combs said in a statement his company planned to launch “in the very near future.”

The Virginia Economic Development Partnership said it worked with Albemarle County to secure the project for the state. Its Virginia Jobs Investment Program will support PS-Fertility’s hiring efforts by providing consultative services and funding to support recruitment and training.

“Virginia is the birthplace of innovations, and PS-Fertility’s groundbreaking discovery demonstrates the importance of our entrepreneurial ecosystems that lead to new technologies and products, ultimately resulting in new jobs,” Caren Merrick, Virginia’s secretary of commerce and trade, said in a statement.

Read more here.

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related